NCPAP联合肺表面活性物质治疗新生儿呼吸窘迫综合征的临床疗效观察

Clinical Study of Therapy for Neonatal Respiratory Distress Syndrome with Pulmonary Surfactant and NCPAP

目的探讨鼻塞式气道正压通气(NCPAP)联合肺表面活性物质治疗新生儿呼吸窘迫综合征的临床疗效观察。方法随机选取我院2011年1月至2013年1月我科室新生儿病房收治入院的经临床诊断为新生儿呼吸窘迫综合征患儿50例作为研究对象,随机分为观察组和对照组,观察组使用NCPAP联合肺表面活性物质进行治疗,对照组采用常规机械通气联合肺表面活性物质治疗,观察两组患儿血气分析比较,以及肺部合并症、氧疗时间、住院时间和住院费用等。结果两组患者治疗上都有一定的疗效,但在氧疗时间及住院费用上观察组明显低于对照组,差异具有统计学意义,P<0.05。观察组肺部感染例数明显低于对照组,P<0.05。结论采用NCPAP联合肺表面活性物质能减少肺部感染等并发症的发生率,减少氧疗时间及住院费用,效果显著,值得推荐应用。

Objective To explore the clinical effect of pulmonary surfactant and NCPAP on neonatal respiratory distress syndrome. Methods Selected randomly 50 cases of newborn infants in our hospital from January 2011 to January 2013 with a confirmed diagnosis of neonatal respiratory distress syndrome were analyzed. These cases were divided into two groups. The experiment group was treated with NPCP and pulmonary surfactant. The control group was treated with Mechanical ventilation and pulmonary surfactant. The clinical syndrome and blood gas analysis of these infants,the readings of the ventilator as well as the complications were studied. Results Both of the groups are efficacy. But the time of oxygen therapy and hospital stays are less than the control group（P〈0.05）. The rate of infection of lung is less than the control group（P〈0.05）. Conclusions The combination of pulmonary surfactant and CPAP could significantly improve the neonatal respiratory distress syndrome within the primary treatment.